Tracers / [18F]FTC-146
[18F]FTC-146
Also written as [18F]FTC-146; [F-18]FTC-146
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- first-in-human
- Syntheses indexed
- 1
What it is
- Compound class
- sigma-1 receptor PET radioligand
- Target / mechanism
- sigma-1 receptor (S1R) PMID 30349360
- Clinical application
- Complex regional pain syndrome (CRPS) PMID 41557146
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | — | 3.3 ± 0.7 % yes | >95 % | — | 28280965 2017 Mol Imaging Biol A reliable and automated radiosynthesis for providing routine clinical-grade [18F]FTC-146 for human studies was established in a modified GE TRACERlab FXFN. — [18F]FTC-146 was synthesized with a radiochemical yield of 3.3 ± 0.7 % and specific radioactivity of 8.3 ± 3.3 Ci/μmol (n = 10, decay corrected to EOB). |
Need this precursor?We can point you to suppliers for [18F]FTC-146, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]FTC-146.
Get in touchNotes
Added from reverse module search (stage 6); 1 article(s) with F-18. | Stage 28: added indication(s) neu-pain from consolidated missing-rubric review.